EICHORCondition: Insomnia Disorder · Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
The main purpose of this study is to assess efficacy of YZJ-1139 for 28 days in adult subjects with insomnia disorder. Efficacy will be evaluated on objective and subjective sleep parameters.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Peking University People's Hospital | Beijing, China | — |
| ChengDu Second People's Hospital | Chengdu, China | — |
| ChongQing Traditional Chinese Medicine Hospital | Chongqing, China | — |
| Deyang People's Hospital | Deyang, China | — |
| The First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital) | Guangzhou, China | — |
| The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital) | Jinan, China | — |
| The Second Affiliated Hospital Of NanChang University | Nanchang, China | — |
| The First Affiliated Hospital of Ningbo University | Ningbo, China | — |
| ShengJing Hospital Of China Medical University | Shenyang, China | — |
| The Third Hospital of Hebei Medical University | Shijiazhuang, China | — |
| SuZhou GuangJi Hospital | Suzhou, China | — |
| The Second Affiliated Hospital of Soochow University | Suzhou, China | — |
+ 4 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06975514